Leap/BeiGene initiate DKN-01+tislelizumab combo mid-stage study in gastric cancer

Leap Therapeutics (NASDAQ:LPTX) up 7.2% in premarket, and BeiGene, (NASDAQ:BGNE) have announced that first patient has been dosed in the DisTinGuish Phase 2a trial, evaluating Leap’s DKN-01, in combination with latter’s tislelizumab, with or without chemotherapy in patients with gastric or gastroesophageal junction cancer (G/GEJ).

The 72-subject trial is designed to evaluate safety, tolerability, and efficacy of the combination therapy of intravenous DKN-01 and tislelizumab ± CAPOX (capecitabine + oxaliplatin) in G/GEJ adenocarcinoma patients.

Leap is conducting this combination study in the U.S. as part of an exclusive license agreement with BeiGene.

https://seekingalpha.com/news/3615618-leap-therapeutics-beigene-initiates-dknminus-01-plustislelizumab-combination-mid-stage-study